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Abstract
Background: Regular use of aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs)
has been consistently associated with reduced risk of colorectal cancer and adenoma, and there is
some evidence for a protective effect for other types of cancer. As experimental studies reveal a
possible role for NSAIDs is reducing the risk of pancreatic cancer, epidemiological studies
examining similar associations in human populations become more important.
Methods: In this hospital-based case-control study, 194 patients with pancreatic cancer were
compared to 582 age and sex-matched patients with non-neoplastic conditions to examine the
association between aspirin use and risk of pancreatic cancer. All participants received medical
services at the Roswell Park Cancer Institute in Buffalo, NY and completed a comprehensive
epidemiologic questionnaire that included information on demographics, lifestyle factors and
medical history as well as frequency and duration of aspirin use. Patients using at least one tablet
per week for at least six months were classified as regular aspirin users. Unconditional logistic
regression was used to compute crude and adjusted odds ratios (ORs) with 95% confidence
intervals (CIs).
Results: Pancreatic cancer risk in aspirin users was not changed relative to non-users (adjusted
OR = 1.00; 95% CI 0.72–1.39). No significant change in risk was found in relation to greater
frequency or prolonged duration of use, in the total sample or in either gender.
Conclusions: These data suggest that regular aspirin use may not be associated with lower risk
of pancreatic cancer.
Background
Regular use of aspirin and other non-steroidal anti-in-
flammatory drugs (NSAIDs) has been consistently associ-
ated with reduced risk of colorectal cancer and adenoma
[1–4], and there is some evidence for a protective effect for
other types of cancer [5–9]. It is widely thought that the
mechanism by which these drugs affect cancer risk is
through the inhibition of the cyclooxygenase (COX) en-
zymes: the constitutively expressed COX-1 and the in-
duced (in most tissues) COX-2 [10]. By inhibiting these
enzymes, NSAIDs can inhibit prostaglandin synthesis, en-
hance cellular immune response, or induce of apoptosis,
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all of which have been postulated to be involved in car-
cinogenesis [11–13].
The cyclooxygenase pathway and NSAIDs have been im-
plicated in pancreatic carcinogenesis, as elevated levels of
COX-2 mRNA and protein have been detected in pancre-
atic carcinomas relative to histologically normal cells [14–
19]. Further, both aspirin [20–22] and other NSAIDs [19]
have been shown to inhibit pancreatic cancer cell prolifer-
ation and induce apoptosis in vitro. Recent studies have
also reported an association between oncogenic ras and
COX-2 expression [23,24]. Since pancreatic tumors tend
to exhibit a high frequency of K-ras mutations [25], the re-
lationship between the K-ras oncogene and COX-2 should
be explored further in vivo. In general, laboratory findings
suggest that COX, especially COX-2, may provide a poten-
tial target for the prevention and possible treatment of
pancreatic cancer.
Few studies have examined COX and pancreatic cancer in
humans, whether it be in clinical or epidemiological stud-
ies. A recent study did not demonstrate an association be-
tween COX-2 expression and pathological or clinical
factors, such as age, gender, survival, tumor size, stage and
vascular invasion [26], confirming results reported in pre-
vious studies [14,17,22]. To our knowledge, only three
population studies, with varying methodological rigor,
have been published examining the relationship between
NSAID use and pancreatic cancer [27–29]. Each of these
studies reported a lack of association. However, a recently
published report on this association, based on a prospec-
tive cohort of 28,283 post-menopausal women, described
a trend of decreasing risk of pancreatic cancer with in-
creased weekly aspirin use [30].
In light of the laboratory evidence and limited number
population-based studies, we conducted a hospital-based
case-control study to further investigate the association
between regular aspirin use and the risk of pancreatic can-
cer.
Methods
The study population included men and women seen at
the Roswell Park Cancer Institute (RPCI) between 1982
and 1998 who completed a comprehensive epidemiolog-
ical questionnaire. Informed consent was obtained from
all participants. The case group was comprised of 194 pre-
dominantly Caucasian (96.6%) patients with pancreatic
cancer identified from the Roswell Park Cancer Institute
tumor registry and diagnostic index, ranging in age from
30 to 84 years. Similarly, the control group included 582
men and women, mostly Caucasian (94.5%), ranging in
age from 27 to 85, who received medical services at RPCI
for non-neoplastic conditions. These individuals came to
RPCI with a suspicion of neoplastic disease, but were not
diagnosed with malignant conditions. Controls were fre-
quency matched to cases by sex and five-year age intervals.
All participants completed the Patient Epidemiology Data
System (PEDS) questionnaire, which is offered to all new
patients, and returned by approximately 50% of patients.
The 16-page instrument covers information on reproduc-
tive and medical histories, family history of cancer, occu-
pational and environmental exposures, tobacco use,
alcohol consumption, and diet. The instrument also as-
sesses aspirin and other medication use prior to the onset
of any current illness, with questions asking how many
times per week the drug was taken, number of years taken
and year of first use. For study purposes, subjects were
classified as regular aspirin users if they had taken the drug
at least once a week for at least one year, and non-users if
they did not meet both of the conditions. Dosage of use
was assessed by comparing non-users to patients report-
ing they had taken aspirin either one to six times per week
or seven or more times per week. Duration of use was
evaluated by comparing non-users to patients reporting
six months to ten years of use or more than ten years. A fi-
nal variable, termed "tablet-years" was created that reflect-
ed both duration and frequency of use (daily use ×  years
of use).
Preliminary analyses were performed to examine descrip-
tive characteristics of the pancreatic cases and hospital
controls, and the association of these characteristics with
risk of developing pancreatic cancer. They consisted of
known and suspected risk factors for pancreatic cancer:
age, education, cigarette smoking, family history of pan-
creatic cancer, race, sex and body mass index. Uncondi-
tional logistic regression analysis was used to compute
odds ratios (ORs) with 95% confidence intervals (CIs). As
packyears of cigarettes smoked smoking (packs per day ×
years of smoking) and family history of pancreatic cancer
were found to be predictors of disease in our data, they
were adjusted for in the regression models, along with
age. In all analyses, non-users of aspirin represented the
reference group.
Results
Descriptive characteristics of pancreatic cancer cases and
hospital controls are shown in Table 1. Cases were more
likely to be smokers, have a family history of pancreatic
cancer, less likely to have schooling beyond high school,
and have a higher BMI.
In this study population, approximately 44% of the cases
and controls were classified as regular aspirin users. Risk
of pancreatic cancer associated with aspirin use is shown
in Table 2. Regular aspirin use was not related to pancre-
atic cancer risk (adjusted OR = 1.00; 95% CI 0.72–1.39).
Increased weekly dosage was not associated with a modi-BMC Public Health 2002, 2 http://www.biomedcentral.com/1471-2458/2/18
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fication in risk (adjusted OR = 0.85; 95% CI 0.49–1.45 for
seven or more tablets per week), but a non-significant in-
crease in risk was observed for increased duration of use
(adjusted OR = 1.21; 95% CI 0.81–1.82 for 11 or more
years of use). Over 11 tablet-years of use was associated
with a reduced risk in the overall set (adjusted OR = 0.65
95% CI 0.37–1.16), although it must be noted that the
95% confidence interval did include unity. This associa-
tion was more pronounced in men than women. In gen-
eral, the risk estimates and 95% confidence intervals
obtained following adjustment for smoking and family
history of pancreatic cancer were very similar to the unad-
justed, crude results.
While stratification based on sex resulted in analysis of
two smaller data sets, results and direction of point esti-
mates were generally similar for men and women com-
pared to each other and the total set. Analyses were also
Table 1: Descriptive characteristics and odds ratios of pancreatic cancer cases and hospital controls – Roswell Park Cancer Institute, 
Buffalo, NY 1982–1996.
Cases (n = 194) Controls (n = 582) OR1 (95% CI)
Age2 62.02 62.07 1.00 (0.98, 1.02)
Education3,5
Up to High School 51 (26.4) 139 (24.0) 1.00
High School 67 (34.7) 182 (32.4) 0.89 (0.55, 1.42)
Some College 34 (17.6) 127 (21.9) 0.72 (0.42, 1.22)
College Graduate 41 (21.2) 132 (22.8) 0.92 (0.54, 1.56)
Cigarette Smoking (pack-years)3,4
None 65 (34.0) 246 (43.6) 1.00
≤  13.5 15 (7.9) 79 (14.0) 0.84 (0.44, 1.59)
14–30 44 (23.0) 83 (14.7) 2.12 (1.30, 3.48)
30.5–52.5 38 (19.9) 76 (13.5) 2.17 (1.32, 3.59)
≤  53 29 (15.2) 80 (14.2) 1.41 (0.82, 2.43)
Family history of pancreatic cancer3
No 183 (94.3) 570 (97.9) 1.00
Yes 11 (5.7) 12 (2.1) 2.65 (1.09, 6.45)
Race3,5
Caucasian 144 (96.6) 494 (94.5) 1.00
African-American 4 (2.7) 26 (5.0) 2.38 (0.23, 24.28)
Other 1 (0.7) 3 (0.6) 0.44 (0.04, 5.53)
Sex3
Female 88 (45.4) 264 (45.4) 1.00
Male 106 (54.6) 318 (54.6) 0.95 (0.65, 1.38)
Body-Mass Index3,6
≤  23 46 (24.7) 144 (25.4) 1.00
23–25.6 32 (17.2) 143 (25.3) 0.68 (0.39, 1.17)
25.7–27.9 52 (28.0) 139 (24.6) 1.20 (0.73, 1.98)
≥  28 56 (30.1) 140 (24.7) 1.27 (0.78, 2.05)
1. odds ratios reported for model including age, education, cigarette smoking, relative with pancreatic cancer, race, sex and body mass index 2. mean 
3. n (%) 4. quartiles based on control distribution after excluding never smokers 5. kg/m2 6. quartiles based on control distributionBMC Public Health 2002, 2 http://www.biomedcentral.com/1471-2458/2/18
Page 4 of 6
(page number not for citation purposes)
performed after restricting the sample to individuals who
were at least 50 years old, with similar results as those pre-
sented in Table 2 (data not shown).
Discussion
Our results do not support the notion that aspirin plays a
role in the development of pancreatic cancer. Most risk es-
timates were close to the null. Unfortunately, the lack of a
Table 2: Risk of pancreatic cancer in association with aspirin use – Roswell Park Cancer Institute, Buffalo, NY 1982–1996.
Cases n (%) Controls n (%) Crude OR (95% CI) Adjusted OR1 (95% CI)
All
Non-Regular User 108(55.7) 327(56.2) 1.00 1.00
Regular User2 86 (44.3) 255(43.8) 1.02 (0.74, 1.42) 1.00 (0.72, 1.39)
Dosage Used
1–6 tabs/wk3 61 (31.4) 157(26.9) 1.18 (0.82, 1.70) 1.15 (0.79, 1.67)
7+ tabs/wk3 25 (12.9) 98 (16.8) 0.87 (0.51, 1.48) 0.85 (0.49, 1.45)
Duration of Use
0.5–10 years3 37 (19.1) 137(23.6) 0.82 (0.54, 1.25) 0.82 (0.54, 1.26)
11+ years3 49 (25.3) 117(20.1) 1.27 (0.85, 1.89) 1.21 (0.81, 1.82)
Tablet-years of Use3
1–10 tablet years 69 (35.6) 176 (30.2) 1.19 (0.83, 1.69) 1.15 (0.80, 1.65)
11+ tablet years 17 (8.8) 79 (13.6) 0.65 (0.37, 1.15) 0.65 (0.37, 1.16)
Men
Non-Regular User 58 (54.7) 174 (54.7) 1.00 1.00
Regular User2 48 (45.3) 144 (45.2) 1.00 (0.64, 1.56) 0.99 (0.64, 1.5)
Dosage Used3
1–6 tabs/wk 31 (29.2) 87 (27.4) 1.07 (0.64, 1.77) 1.05 (0.63, 1.75)
7+ tabs/wk 17 (16.0) 57 (17.9) 0.90 (0.48, 1.66) 0.91 (0.49, 1.70)
Duration of Use3
0.5–10 years 27 (25.5) 81 (25.5) 1.00 (0.59, 1.69) 1.03 (0.60, 1.75)
11+ years 21 (19.8) 63 (19.8) 1.00 (0.56, 1.78) 0.95 (0.53, 1.72)
Tablet-years of Use3
1–10 tablet years 43 (40.6) 113 (35.5) 1.14 (0.72, 1.81) 1.12 (0.70, 1.78)
11+ tablet years 5 (4.7) 31 (9.7) 0.48 (0.18, 1.30) 0.52 (0.19, 1.40)
Women
Non-Regular User 50 (56.8) 153 (59.0) 1.00 1.00
Regular User2 38 (43.2) 111 (42.0) 1.05 (0.64, 1.71) 1.01 (0.62, 1.67)
Dosage Used3
1–6 tabs/wk 30 (34.1) 70 (26.5) 1.31 (0.77, 2.24) 1.29 (0.75, 2.23)
7+ tabs/wk 4 (9.1) 41 (15.5) 0.77 (0.24, 2.40) 0.67 (0.21, 2.14)
Duration of Use3
0.5–10 years 10 (11.4) 56 (21.2) 0.55 (0.26, 1.15) 0.55 (0.26, 1.16)
11+ years 28 (31.8) 54 (20.5) 1.59 (0.91, 2.77) 1.52 (0.86, 2.69)
Tablet-years of Use3
1–10 tablet years 26 (29.5) 63 (23.9) 1.26 (0.72, 2.21) 1.25 (0.70, 2.20)
11+ tablet years 12 (13.6) 48 (18.2) 0.77 (0.38, 1.55) 0.72 (0.35, 1.49)
1. Odds ratio adjusted for age, packyears of smoking and family history of pancreatic cancer. 2. Regular use defined as self-reported use for at least 
once a week for six consecutive months. 3. Among regular users.BMC Public Health 2002, 2 http://www.biomedcentral.com/1471-2458/2/18
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coherent pattern or trend in the risk estimates preclude
conclusions based on integrating the results.
Our results contrast with those reported by Anderson et al.
[30], who demonstrated a significant, dose-dependent, re-
duced risk in a cohort of 28,283 post-menopausal wom-
en. We observed a suggestion of increased risk in women
associated with duration of use, but analyses of cases by
menopausal status were limited by small numbers. Fur-
ther, this non-significant risk reduction is difficult to inter-
pret, due to the inverse association with regular use and
dose in women.
Three other studies have also examined NSAID use and
pancreatic cancer risk [27–29]. While these studies had
similar null results, they differed in their assessment of
NSAID use. Langman et al. [29] used a general practice re-
search database from the United Kingdom that included
data on morbidity and NSAID prescriptions. For 12,174
incident cancer cases (396 pancreas) and 34,934 controls,
information on NSAID prescriptions for 13–36 months
prior to cancer diagnosis (equivalent information for con-
trols) was extracted for the period of 1993–1995. Associa-
tions between risk of cancer and number of prescriptions
were analyzed, with no association being found for pan-
creatic cancer. Gridley et al. [27] examined the incidence
of cancer among 11,683 Swedish rheumatoid arthritis pa-
tients, testing the hypothesis that individuals who were
taking regular amounts of NSAIDs would have lower can-
cer rates. Of the 840 cancer cases occurring from 1965 to
1983, 32 had pancreatic cancer. Using regional cancer
rates, standardized incidence ratios (SIR) were calculated.
There was a slightly reduced risk for pancreatic cancer, al-
though this risk was not significant (SIR = 0.83, 95% CI
0.6–1.2). There was no information on individual doses.
Finally, Coogan et al. [28] examined the association be-
tween NSAID use and risk of digestive cancers in a hospi-
tal-based case-control study. Included in the overall group
were 504 pancreatic cancer patients and 595 controls. De-
fining regular NSAID use as use for at least four days per
week for at least three months, initiated at least one year
before hospital admission, they found a slight negative as-
sociation between NSAID use and risk of pancreatic can-
cer (continual vs. never users OR = 0.8, 95% CI 0.5–1.1;
use over 5 years vs. never users OR = 0.6, 95% CI 0.4–1.1).
In general, while the methodology and exposure assess-
ment of these three studies differed greatly, a lack of asso-
ciation between NSAID use and pancreatic cancer risk or
incidence, as represented by risk estimates and confidence
intervals, was reported.
Our null findings may be related to the possibility that,
prior to cancer diagnosis or because of associated condi-
tions or complications, cases experienced sufficient dis-
comfort to warrant aspirin usage. Unfortunately, reasons
for aspirin use were not available. Exposure misclassifica-
tion of aspirin use, likely to be non-differential, may have
also caused attenuation of the results, since the analyses
were based on self-reported aspirin use and was based on
number of pills taken, and not the actual dose of aspirin.
The hospital-based design, although potentially reducing
recall bias, may lessen the generalizability of our findings
to the general population. However, it is unlikely that self-
reported aspirin use would be different for patients treated
at RPCI than for those treated at other facilities. We at-
tempted to minimize this source of bias by randomly se-
lecting controls from a large pool of eligible patients from
a wide variety of diagnostic groups. Only about 50% of el-
igible cases and controls completed the PEDS question-
naire, likely to further introduce a selection bias. We had
no way to ascertain whether those that refused to partici-
pate differed with respect to aspirin use. Despite these lim-
itations, it should be pointed out that numerous previous
studies that have utilized the PEDS database, and faced
the same methodological issue, have consistently replicat-
ed established epidemiological associations for a variety
of cancer sites [31–35]. Further, as mentioned above,
smoking and family history of pancreatic cancer are two of
the few established risk factors for pancreatic cancer [36],
and they were found to be associated with disease risk in
our data. Other limitations of this study include the po-
tential biases inherent in case-control studies.
The primary strengths of our study are the different types
of exposure variables and size. In examining general use,
as well as frequency and duration, it is possible to see
which measure of aspirin use, if any, is associated with
pancreatic cancer risk, and not rely solely on more general
categorical designations like regular vs. non-users. Fur-
ther, the rareness and aggressive nature of this cancer
makes it difficult to conduct large retrospective popula-
tion studies. Because of the large number of patients seen
at the Roswell Park Cancer Institute over the long study
period (1982–1998), close to 200 pancreatic cancer pa-
tients were included in the analysis.
Conclusions
To summarize, in this hospital based case-control study of
pancreatic cancer, we found no association between aspi-
rin use and risk. Since it is widely thought that COX-2,
more so than COX-1, may play a role in neoplasia, it is
reasonable to think that the more effective drugs would be
selective for COX-2. These agents address the different
physiologic roles of the two COX enzymes as well as re-
duce adverse side effects of prolonged drug use [37]. Nev-
ertheless, as discussed above, certain experimental and
population studies [20–22] do indicate that drugs like as-
pirin, which can act on both COX-1 and 2, may play a role
in prevention and therapy of pancreatic cancer. Given the
biologic plausibility for a potential chemopreventive ef-BMC Public Health 2002, 2 http://www.biomedcentral.com/1471-2458/2/18
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fect of aspirin and other NSAIDs on pancreatic cancer risk,
additional analytic epidemiological studies are needed to
further explore this risk association. These studies should
incorporate more detailed information on aspirin other
NSAIDs, especially selective COX-2 inhibitors, in order to
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